Roadmap

From Non-Oncology to Oncology — Entering a Larger Market
From Hematologic to Solid Tumors — Reaching More Patients

Non-Oncology

Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS)

Oncology

Initial Market Entry: Hematologic Malignancies

Lower barriers to regulatory approval

Eligible for fast-track review

Orphan drug market exclusivity

Lymphoma

 (CTCL/DLBCL/Others)

Expansion into Solid Tumor Cancer Therapies

Broad range of potential indications

Compatible with multiple cancer SOCs

Combination with Chemo-radiotherapy

 (IIT Trial in Rectal Cancer)

Combination with Immunotherapy

(IIT Trial in Lung & Breast Cancer)

Combination with Cell Therapy

(Collaboration with CAR-T biocompanies)

Continuously Expanding Indications

Gain more support from pharmaceutical companies and research physicians

A two-pronged approach utilizing both SIT and IIT

Cost savings and maximized benefits

Note: SIT = Sponsor-Initiated Trial (company-led); IIT = Investigator-Initiated Trial (physician-led), typically lower cost for the company.